17Mar 2023
Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis

Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis

The E-APLICOV study followed up on the APLICOV-PC study to assess the long-term safety and efficacy of plitidepsin in hospitalized adult patients with COVID-19. Out of 45 patients who received plitidepsin therapy in the original study, 34 were enrolled in E-APLICOV. The study found that there were no significant adverse events or complications reported during the follow-up period. Only 5 patients experienced another COVID-19 episode after discharge, and none of them required hospital readmission. The study concluded that plitidepsin has a favorable long-term safety profile in adult patients hospitalized for COVID-19, with a low rate of post-COVID-19 complications.

  • #family health

Like

Save

Share